Creating a new CAR-T therapy for blood cancers like AML and glioblastoma
Official title: Development of a novel pan-cancer CAR-T product against AML and Glioblastoma
Funded at Kure. Ai, INC. · NIH-11007100 · Data updated 2026-11-12
This study is testing a new type of CAR-T cell therapy that aims to help people with tough cancers like acute myeloid leukemia and glioblastoma by training the immune cells to find and attack cancer cells that show a special marker called MR1.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Kure. Ai, INC. NIH-funded |
| Lab location | 1 site (Shaker Heights, United States) |
| Project start | September 16, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $400,000 |
| NIH project number | 1R43CA295241-01 |
| Project ID | NIH-11007100 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research would include patients diagnosed with acute myeloid leukemia or glioblastoma who have not responded to standard treatments.
✕Less likely to help
Patients with early-stage cancers or those not diagnosed with AML or glioblastoma may not benefit from this research.
What this research studies
This research focuses on developing a novel CAR-T cell therapy targeting acute myeloid leukemia (AML) and glioblastoma, which are challenging cancers to treat. The approach involves using a unique target, the MR1 molecule, which is typically hidden inside cells but can appear on the surface of tumor cells when bound to specific cancer-related metabolites. By designing CAR-T cells that can recognize and attack these MR1-expressing tumor cells, the research aims to improve treatment outcomes for patients with these malignancies. The initial studies in mice have shown promising safety and efficacy results, paving the way for potential human applications.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with AML and glioblastoma, potentially improving survival rates and quality of life.
How similar studies have gone: While CAR-T therapies have shown success in treating certain blood cancers, this specific approach targeting MR1 in solid tumors and blood cancers is novel and has not been widely tested.
Where this research is happening
-
Kure. Ai, INC.
Shaker Heights, United States Active
Researchers
- Principal investigator: Soler, David — Kure. Ai, INC.
- Study coordinator: Soler, David
Related research
Other NIH-funded projects on the same topics.
-
Small molecules to block Slit2/ROBO in glioblastoma
A study to test small molecule drugs that block Slit2/ROBO signals to help treat glioblastoma in patients.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
Small-molecule and biologic treatments for glioblastoma using targeted brain delivery
A new approach aims to use FPS-ZM1 to shrink brain swelling and support immunotherapy for glioblastoma, potentially helping patients recover after surgery.
-
Targeted therapies for glioblastoma in adults and kids
A large NIH program is exploring new brain cancer therapies, including drugs that reach the brain and work against glioblastoma in both children and adults.
-
6-thio-2'-deoxyguanosine for glioblastoma: a new approach to target tumors before surgery
A trial tests a novel drug given before glioblastoma surgery to see how it behaves in the body and within the tumor, and to learn how it affects cancer cells and the immune environment.
-
CD38-Driven Changes in Brain Tumor Metabolism and Immunity in Glioblastoma
A patient-facing look at how scientists plan to study how glioblastoma grows by changing its metabolism and dampening the immune response, with potential targets to help treatment in the future.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.